Results of univariate and multivariate analysis of survival at 2 years
| Covariate . | No. . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|
| Hazard ratio . | 95% confidence interval . | P* . | Hazard ratio . | 95% confidence interval . | P* . | ||
| Age | |||||||
| Younger than 30 y | 1 | 1 | — | — | — | — | — |
| 30 to 39 y | 26 | 0.47 | 0.16-1.32 | .15 | — | — | — |
| 40 to 49 y | 24 | 0.46 | 0.16-1.33 | .15 | — | — | — |
| 50 y or older | 8 | 1.24 | 0.37-4.1 | .7 | — | — | — |
| CD4 cell count | |||||||
| Higher than 500 × 106/L | 15 | 1 | — | — | — | — | — |
| 201 to 500 × 106/L | 26 | 1.31 | 0.5-3.42 | .5 | — | — | — |
| 200 × 106/L or lower | 22 | 3.4 | 1.33-8.7 | .01 | 2.84 | 1.09-7.36 | .032 |
| CD8 cell count | |||||||
| 1500 × 106/L or lower | 39 | 1 | — | — | — | — | — |
| Higher than 1500 × 106/L | 21 | 2.8 | 1.22-6.4 | .015 | 1.5 | 0.59-3.81 | .38 |
| History of AIDS | |||||||
| No | 50 | 1 | — | — | — | — | — |
| Yes | 13 | 1.3 | 0.59-2.8 | .5 | — | — | — |
| HAART at entry | |||||||
| Yes | 31 | 1 | — | — | — | — | — |
| No | 32 | 1.02 | 0.55-1.96 | .95 | — | — | — |
| Nadir CD4 cell count | |||||||
| Higher than 100 × 106/L | 37 | 1 | — | — | — | — | — |
| 100 × 106/L or lower | 18 | 2.03 | 1.01-4.05 | .044 | 1.69 | 0.75-3.82 | .19 |
| Plasma HIV RNA | |||||||
| More than 50 copies/mL | 44 | 1 | — | — | — | — | — |
| Less than 50 copies/mL | 16 | 0.53 | 0.26-1.06 | .075 | 1.13 | 0.42-3.04 | .8 |
| Absolute lymphocyte count | |||||||
| More than 1000 × 106/L | 53 | 1 | — | — | — | — | — |
| 1000 × 106/L or less | 10 | 3.16 | 1.47-6.76 | .003 | 1.34 | 0.46-3.86 | .58 |
| ECOG | |||||||
| 0, 1, 2 | 24 | 1 | — | — | — | — | — |
| More than 2 | 39 | 3.05 | 1.43-6.49 | .004 | 2.58 | 1.18-5.62 | .017 |
| “B” symptoms | |||||||
| No | 12 | 1 | — | — | — | — | — |
| Yes | 51 | 2.8 | 0.99-7.97 | .051 | 1.18 | 0.47-6.97 | .38 |
| Bulky disease | |||||||
| No | 43 | 1 | — | — | — | — | — |
| Yes | 19 | 1.63 | 0.82-3.22 | .16 | — | — | — |
| LDH levels | |||||||
| Normal value (N) or lower | 3 | 1 | — | — | — | — | — |
| More than N to 5N or less | 32 | 1.87 | 0.25-14.06 | .54 | — | — | — |
| More than 5N | 28 | 2.91 | 0.38-21.76 | .3 | — | — | — |
| Histologic subtype | |||||||
| Classical BL | 38 | 1 | — | — | — | — | — |
| BLL or BLP | 25 | 1.31 | 0.68-2.52 | .4 | — | — | — |
| Cytogenetic study | |||||||
| Ig-myc only | 13 | 1 | — | — | — | — | — |
| Complex | 11 | 2.5 | 0.79-8.08 | .116 | — | — | — |
| Peripheral blasts | |||||||
| No | 46 | 1 | — | — | — | — | — |
| Yes | 17 | 1.35 | 0.66-2.7 | .4 | — | — | — |
| CSF leukemia | |||||||
| No | 51 | 1 | — | — | — | — | — |
| Yes | 12 | 0.99 | 0.43-2.26 | .98 | — | — | — |
| Cranial nerve palsy or spinal cord injury | |||||||
| No | 30 | 1 | — | — | — | — | — |
| Yes | 18 | 1.14 | 0.52-2.5 | .72 | — | — | — |
| Hemoglobin level | |||||||
| Higher than 10 g/L | 270 | 10 | — | — | — | — | — |
| 10 g/dL or lower | 360 | 14 | 7.6-27.8 | .25 | — | — | — |
| Platelet level | |||||||
| More than 100 × 109/L | 45 | 1 | — | — | — | — | — |
| 100 × 109/L or less | 18 | 1.63 | 0.83-3.2 | .15 | — | — | — |
| IPI | |||||||
| 0,1,2,3 | 19 | 1 | — | — | — | — | — |
| More than 3 | 44 | 2.23 | 1.01-4.89 | .045 | 0.49 | 0.12-2.03 | .33 |
| MTX at COPADM1 | |||||||
| Dosage higher than 75% | 44 | 1 | — | — | — | — | — |
| Dosage 75% or lower | 18 | 1.69 | 0.84-3.33 | .14 | — | — | — |
| Covariate . | No. . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|
| Hazard ratio . | 95% confidence interval . | P* . | Hazard ratio . | 95% confidence interval . | P* . | ||
| Age | |||||||
| Younger than 30 y | 1 | 1 | — | — | — | — | — |
| 30 to 39 y | 26 | 0.47 | 0.16-1.32 | .15 | — | — | — |
| 40 to 49 y | 24 | 0.46 | 0.16-1.33 | .15 | — | — | — |
| 50 y or older | 8 | 1.24 | 0.37-4.1 | .7 | — | — | — |
| CD4 cell count | |||||||
| Higher than 500 × 106/L | 15 | 1 | — | — | — | — | — |
| 201 to 500 × 106/L | 26 | 1.31 | 0.5-3.42 | .5 | — | — | — |
| 200 × 106/L or lower | 22 | 3.4 | 1.33-8.7 | .01 | 2.84 | 1.09-7.36 | .032 |
| CD8 cell count | |||||||
| 1500 × 106/L or lower | 39 | 1 | — | — | — | — | — |
| Higher than 1500 × 106/L | 21 | 2.8 | 1.22-6.4 | .015 | 1.5 | 0.59-3.81 | .38 |
| History of AIDS | |||||||
| No | 50 | 1 | — | — | — | — | — |
| Yes | 13 | 1.3 | 0.59-2.8 | .5 | — | — | — |
| HAART at entry | |||||||
| Yes | 31 | 1 | — | — | — | — | — |
| No | 32 | 1.02 | 0.55-1.96 | .95 | — | — | — |
| Nadir CD4 cell count | |||||||
| Higher than 100 × 106/L | 37 | 1 | — | — | — | — | — |
| 100 × 106/L or lower | 18 | 2.03 | 1.01-4.05 | .044 | 1.69 | 0.75-3.82 | .19 |
| Plasma HIV RNA | |||||||
| More than 50 copies/mL | 44 | 1 | — | — | — | — | — |
| Less than 50 copies/mL | 16 | 0.53 | 0.26-1.06 | .075 | 1.13 | 0.42-3.04 | .8 |
| Absolute lymphocyte count | |||||||
| More than 1000 × 106/L | 53 | 1 | — | — | — | — | — |
| 1000 × 106/L or less | 10 | 3.16 | 1.47-6.76 | .003 | 1.34 | 0.46-3.86 | .58 |
| ECOG | |||||||
| 0, 1, 2 | 24 | 1 | — | — | — | — | — |
| More than 2 | 39 | 3.05 | 1.43-6.49 | .004 | 2.58 | 1.18-5.62 | .017 |
| “B” symptoms | |||||||
| No | 12 | 1 | — | — | — | — | — |
| Yes | 51 | 2.8 | 0.99-7.97 | .051 | 1.18 | 0.47-6.97 | .38 |
| Bulky disease | |||||||
| No | 43 | 1 | — | — | — | — | — |
| Yes | 19 | 1.63 | 0.82-3.22 | .16 | — | — | — |
| LDH levels | |||||||
| Normal value (N) or lower | 3 | 1 | — | — | — | — | — |
| More than N to 5N or less | 32 | 1.87 | 0.25-14.06 | .54 | — | — | — |
| More than 5N | 28 | 2.91 | 0.38-21.76 | .3 | — | — | — |
| Histologic subtype | |||||||
| Classical BL | 38 | 1 | — | — | — | — | — |
| BLL or BLP | 25 | 1.31 | 0.68-2.52 | .4 | — | — | — |
| Cytogenetic study | |||||||
| Ig-myc only | 13 | 1 | — | — | — | — | — |
| Complex | 11 | 2.5 | 0.79-8.08 | .116 | — | — | — |
| Peripheral blasts | |||||||
| No | 46 | 1 | — | — | — | — | — |
| Yes | 17 | 1.35 | 0.66-2.7 | .4 | — | — | — |
| CSF leukemia | |||||||
| No | 51 | 1 | — | — | — | — | — |
| Yes | 12 | 0.99 | 0.43-2.26 | .98 | — | — | — |
| Cranial nerve palsy or spinal cord injury | |||||||
| No | 30 | 1 | — | — | — | — | — |
| Yes | 18 | 1.14 | 0.52-2.5 | .72 | — | — | — |
| Hemoglobin level | |||||||
| Higher than 10 g/L | 270 | 10 | — | — | — | — | — |
| 10 g/dL or lower | 360 | 14 | 7.6-27.8 | .25 | — | — | — |
| Platelet level | |||||||
| More than 100 × 109/L | 45 | 1 | — | — | — | — | — |
| 100 × 109/L or less | 18 | 1.63 | 0.83-3.2 | .15 | — | — | — |
| IPI | |||||||
| 0,1,2,3 | 19 | 1 | — | — | — | — | — |
| More than 3 | 44 | 2.23 | 1.01-4.89 | .045 | 0.49 | 0.12-2.03 | .33 |
| MTX at COPADM1 | |||||||
| Dosage higher than 75% | 44 | 1 | — | — | — | — | — |
| Dosage 75% or lower | 18 | 1.69 | 0.84-3.33 | .14 | — | — | — |
— indicates not applicable; HAART, indicates highly active antiretroviral therapy; Ig-myc, t(8;14), t(8;22) or t(2;8); CSF, cerebrospinal fluid; and MTX, methotrexate.
Likelihood ratio test.